NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

Pulse Biosciences (PLSE): Assessing Valuation Following Modest Share Rebound and Recent Slowdown

Pulse Biosciences (PLSE) shares have edged up slightly in recent trading, gaining just under 2% following a stretch of losses this month. The move comes as investors reassess the company’s outlook in light of continued volatility in the healthcare sector. See our latest analysis for Pulse Biosciences. This latest rebound offers a bit of relief for Pulse Biosciences after a tough run that saw the share price slump over the past month. The company’s three-year total shareholder return is still...
NYSE:VRTS
NYSE:VRTSCapital Markets

Virtus Investment Partners (VRTS): Evaluating the Value Opportunity After Recent Share Price Weakness

Virtus Investment Partners (VRTS) shares have come under pressure over the past month, declining 16%. Investors are taking a closer look at the stock’s trajectory and considering potential catalysts that could shape its direction. See our latest analysis for Virtus Investment Partners. After a tough 30-day stretch for Virtus Investment Partners, with a share price return of -15.5%, the year-to-date slide has extended to -26.1%. Momentum looks decidedly challenged, and the past year’s total...
NYSE:BORR
NYSE:BORREnergy Services

Is Surging Rig Utilization and Contract Wins Altering the Investment Case for Borr Drilling (BORR)?

Borr Drilling Limited recently reported its third quarter 2025 results, posting US$277.1 million in revenue and US$27.8 million in net income, both increasing significantly from the same period last year. An unusually high rig utilization rate and continued contract wins, particularly in markets like Saudi Arabia and Mexico, highlight robust operational momentum for the company. We'll examine how Borr Drilling's increased rig activity and new contract commitments could affect the company's...
NasdaqGS:VRSN
NasdaqGS:VRSNIT

Does Ongoing Insider Selling at VeriSign (VRSN) Signal Shifts in Management’s Long-Term Conviction?

On November 13, 2025, VeriSign's Executive Chairman, President, and CEO, D Bidzos, sold 9,000 shares of the company according to an SEC filing. This sale adds to a pattern of insider selling, as the CEO has sold a total of 108,000 shares over the past year without making any purchases, highlighting ongoing executive share sales. We'll now examine how recent insider selling by VeriSign's CEO may influence the company's investment narrative and investor confidence. Find companies with...
NYSE:HAE
NYSE:HAEMedical Equipment

Is Haemonetics’ (HAE) Shift to Profitability and Buybacks a New Capital Allocation Play?

Haemonetics Corporation recently reported second quarter results, showing a year-over-year sales decline to US$327.32 million but an increase in net income to US$38.68 million and earnings per share to US$0.81; the company also completed a buyback of 1,430,579 shares, around 2.97% of its outstanding stock, for US$75 million. This combination of higher earnings and reduced share count highlights management's focus on profitability and capital returns despite softer top-line performance. We’ll...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Soars 135% as FDA Milestones Spark Valuation Debate for 2025

Ever wondered if BridgeBio Pharma's wild ride means it's a smart buy or just hyped up? This article takes a closer look at the real value, so you know what you’re really getting into. The stock has soared with a jaw-dropping 135.4% gain so far this year and is up an incredible 179.9% over the past year, making many investors take a closer look. Headlines have focused on BridgeBio's clinical trial successes and fresh partnerships, fueling optimism and driving the stock...
NasdaqGS:HWC
NasdaqGS:HWCBanks

Did Hancock Whitney's (HWC) Strong Q3 Earnings and Buyback Signal a Shift in Its Growth Story?

In November 2025, Hancock Whitney reported third-quarter earnings that exceeded expectations, fueled by increases in both non-interest and net interest income, and announced plans to repurchase an additional 443,700 shares. The company provided forward guidance highlighting anticipated growth in loan balances, deposit growth, modestly rising net interest income, and further margin expansion, reflecting confidence in its ongoing strategy. Hancock Whitney’s management also outlined a...
NYSE:ARCO
NYSE:ARCOHospitality

Arcos Dorados (NYSE:ARCO): Assessing Valuation After Recent Modest Share Price Bump

Arcos Dorados Holdings (NYSE:ARCO) has been drawing attention with its recent stock movement and underlying performance. Investors are looking into how its fundamentals and recent trends might shape sentiment, particularly over the past month. See our latest analysis for Arcos Dorados Holdings. While Arcos Dorados Holdings has seen a modest bump lately, with a 1-month share price return of just over 5%, the bigger picture shows momentum has yet to turn the tide. Over the past year, total...